Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma

Alberto Fabbri, Mariapia Lenoci, Alessandro Gozzetti, Ida Chitarrelli, Francesca Olcese, Donatella Raspadori, Marco Gobbi, Francesco Lauria

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-five elderly patients with untreated indolent non-Hodgkin lymphoma were treated with oral fludarabine 25 mg/m2/d (40 mg total dose) and cyclophosphamide 150 mg/m2/d, both for four consecutive days, repeated every 28 d for four cycles. In all, 21 (84%) patients were responsive: 10 patients achieved complete remission while partial response was obtained in 11. During an observation period of 37 months, there was an overall survival rate of 70% and a median event-free survival of 20 months. Haematological and extra-haematological toxicity were mild. This reduced-dose Flu-based oral regimen showed good efficacy and was simple to administer on an outpatient basis.

Original languageEnglish
Pages (from-to)90-93
Number of pages4
JournalBritish Journal of Haematology
Volume139
Issue number1
DOIs
Publication statusPublished - Oct 2007

Keywords

  • Cyclophosphamide
  • Elderly
  • Indolent non-Hoddgkin lymphoma
  • Low-dose
  • Oral fludarabine

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this